Scientist in front of whiteboard
icon-epigenetics

Next-Generation Sequencing

QIAseq Multimodal: Explore the power of one
New! QIAseq Pan-cancer Multimodal Panel for comprehensive genomic profiling of solid tumors and heme malignancies

Experience our innovative, single-day sample to sequencing workflow for simultaneous enrichment and profiling of 605 relevant DNA variant and RNA fusion biomarkers found across multiple cancers, as well as assessment of tumor mutational burden (TMB) and microsatellite instability (MSI), from a single sample input of 10 ng.

QIAseq Pan-cancer Multimodal Panel
Unlock insights into multiple cancers with just 10 ng total nucleic acid input.
Targets genes and RNA fusions implicated in the pathogenesis of solid and heme malignancies
  • Gene targets: Covers exonic regions + 5–10 bases of exon/intron junctions
  • RNA fusions: Targets transcripts in COSMIC, covers exons in both 3’ and 5’ directions
  • Includes full coverage of TERT promoter

Assess key immunotherapy biomarkers:

  • TMB: Coverage of >1 Mb enables statistically significant assessment of tumor mutation load
  • MSI status: 26 loci with well-established utility for correlation to treatment response
QIAseq Tumor Mutational Burden Panels

Enables detection of

  • DNA variants: SNVs, Indels, CNVs
  • RNA: fusions, gene expression, exon skipping events
  • Biomarkers: TMB, MSI

Starting material

  • DNA: 10–40 ng
  • RNA: 10–250 ng
  • Total nucleic acid: 10–40 ng

Sample types

  • FFPE samples, whole blood, cells and tissues

Unique molecular indices (UMIs) and Unique dual indices (UDIs) included

  • Confidently detect low-frequency variants by incorporating UMIs
  • Reduce index hopping and read mis-assignment with UDIs
QIAseq Multimodal
  • Single NGS workflow for DNA and RNA analysis from a single sample
    In this webinar, Dr. Herold will discuss how her team has streamlined the profiling of cancer-associated alterations by using a single workflow for the construction of libraries from total nucleic acids for sequencing on Illumina platforms to achieve high operational efficiency.
    Single NGS workflow
  • Part 1: One-day workflow for simultaneous profiling of DNA variants and RNA fusions
    In this webinar, we explore a new workflow for simultaneous NGS profiling of both DNA variants and RNA fusions, as well as gene expression in just one day, using as little as 10 ng sample.
    QIAseq Multimodal
  • Part 2: Curated panels and custom workflows for profiling DNA and RNA biomarkers in parallel
    In this webinar, we will take you through an introduction and live demo of the QIAGEN CLC Genomics Workbench workflow for multimodal analysis. Discover this intuitive yet powerful solution tailored for analysis of NGS data generated with QIAseq Multimodal Panels.
    Bioinformatics
  • Evolution of tumor profiling in a clinical lab
    In this webinar, Vincent Funari of NeoGenomics will discuss how his team has evolved its profiling approaches for both heme and solid tumors from targeted panels to more comprehensive genomic profiling.
    Two young scientist having a webinar
  • Simultaneous detection of DNA variants and RNA fusions
    In this webinar, we’ll discuss customized solutions for optimized workflows to address specific applications, powered by our Enterprise Genomics Services (EGS). This is a concierge-style approach to project design and management, built upon years of experience in development and rapid integration of custom solutions into the laboratory.
    Team work
  • Single NGS workflow
    Single NGS workflow for DNA and RNA analysis from a single sample
  • QIAseq Multimodal
    Part 1: One-day workflow for simultaneous profiling of DNA variants and RNA fusions
  • Bioinformatics
    Part 2: Curated panels and custom workflows for profiling DNA and RNA biomarkers in parallel
  • Two young scientist having a webinar
    Evolution of tumor profiling in a clinical lab
  • Team work
    Simultaneous detection of DNA variants and RNA fusions
All photos taken prior to COVID-19
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm